Tao K.-Y.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute |
Li X.-X.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute |
Xu W.-Z.,China Institute of Technology |
Wang Y.,Physical Examination Center |
And 5 more authors.
OncoTargets and Therapy | Year: 2015
Background: Single-nucleotide polymorphisms in apoptosis-related genes have been shown to play a role in the efficacy of platinum-based chemotherapy and may influence clinical outcomes. Our study aimed to evaluate the correlations of four functional single-nucleotide polymorphisms - FAS -670 A>G, FAS ligand -844 T>C, survivin -31 G>C, and survivin 9386 C>T – with drug response and clinical outcomes in advanced non-small-cell lung cancer patients who received platinum-based chemotherapy.Materials and methods: Polymorphisms were evaluated using the polymerase chain reaction-based restriction fragment-length polymorphism technique.Results: Patients with the CC genotype of FAS -670 A>G had worse overall survival (OS) than those with the CT or TT genotype (P=0.044), with median OS values of 20.1 months, 22.8 months, and 26.0 months, respectively. Furthermore, progression-free survival was associated with the FAS -670 A>G polymorphism (P=0.032). In addition, patients with the TC and CC genotypes of survivin 9386 C>T experienced improved survival compared with patients with the TT genotype (median OS 31.4 months and 22.8 months, respectively).Conclusion: The functional FAS -670 A>G and survivin 9386 C>T polymorphisms are potential independent prognostic factors in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. © 2015 Tao et al. Source
Zheng Z.-G.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute |
Yu H.-Q.,Rockefeller University |
Ling Z.-Q.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute |
Mou H.-Z.,Zhejiang Cancer Hospital Zhejiang Cancer Research Institute |
And 2 more authors.
Protein and Peptide Letters | Year: 2011
Mass spectrometric profiling using ProteinChip and magnetic beads has rapidly grown over the past years, particularly to generate serum profiles for cancer diagnosis. The molecular weights of these distinguishing peaks are usually under 30 kDa. To identify those low molecular weight proteins and peptides is important for specific assays to be developed and increases biological insight. In this study, low molecular weight proteins and peptides from serum were purified by a combination of weak cation exchange magnetic beads and high performance liquid chromatography. The purified proteins and peptides were analyzed by 1D SDS PAGE, SELDI and LC-MS/MS. 246 proteins were identified from the HPLC fractions by LC-MS/MS. 95(38.62%) proteins were first identified in serum compare with Sys-BodyFluid database. 11(11/96) proteins were documented cancer associated proteins. We also observed about 109 proteins/peptides in SELDI mass spectrum, and 13 of the SELDI features were identified. Copyright © 2011 Bentham Science Publishers Ltd. Source